TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06082635
• Other study ID #: TGRX-326-3001-NSCLC-CN
• Status: Recruiting
• Phase: Phase 3
• Start date: December 14, 2023
• Est. completion date: November 30, 2028

Study information

• Verified date: January 2024
• Source: Shenzhen TargetRx, Inc.
• Contact: Bing Liu
• Phone: (+86)18629418910
• Email: bing.liu[@]tjrbiosciences.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC

Description:

This Phase III study aims to evaluate the safety profile and efficacy profile in patients with ALK-positive advanced or metastatic NSCLC and to compare the efficacy and safety of TGRX-326 with that of crizotinib. The primary purpose of this study is to evaluate and compare the efficacy profile of TGRX-326 with crizotinib, with progression-free survival (PFS) as evaluated by independent review committee (IRC) as end point. Secondary objectives include comparing efficacy profile of other endpoints and safety profiles of the investigational drug with crizotinib. Exploratory objective includes the evaluation of population pharmacokinetic (PK) profile of TGRX-326 and efficacy of TGRX-326 in ALK-positive advanced NSCLC patients determined as progressive disease after crizotinib treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 297
• Est. completion date: November 30, 2028
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing to follow the treatment protocol and visit schedule, and participate in the study with the ICF signed;

• = 18 years of age on the day of ICF signing, regardless of gender.

• Diagnosed as incurable stage IIIB - IV ALK-positive NSCLC;

• Providing prior ALK positive test results at screening;

• Naïve to ALK-inhibitor; patients could be intolerant or have progressive disease from previous first-line chemotherapy;

• Patients could have metastases to central nervous system at screening if the condition is asymptomatic, stable or completely recovered;

• At least one measurable lesion;

• An ECOG PS score within 0-2;

• Adequate bone marrow, liver, kidney, coagulation and pancreatic functions;

• Expected survival = 3 months;

• Willing to take effective contraceptive measures (for men of reproductive potential and women of reproductive age only) from ICF signing to 6 months after last administration of the investigational drug. Women of reproductive age include women before menopause and within 1 year after menopause; those women must have a negative pregnancy test = 7 days prior to the first dose of the investigational drug.

Exclusion Criteria:

• Known hypersensitivity to any of the active ingredients or excipients of TGRX-326 or crizotinib pills; or a history of severe allergic reactions;

• Having another type of cancer except for lung cancer;

• Radiotherapy within 14 days prior to the first dose;

• Received other systemic anti-tumor treatment within 4 weeks prior to the first dose, or is within 5 half-lives of the said treatment; received traditional Chinese medicine indicated for anti-tumor purposes within 14 days prior to the first dose;

• Major surgery within 4 weeks prior to the first dose;

• Spinal cord compression caused by tumor, unless the subject achieves significant pain control and full recovery of neurological function within 4 weeks prior to the first dose.

• Abnormal gastrointestinal function that affect absorption within the past 6 months;

• History of active pneumonia or clinically significant interstitial pneumonia, or radiation or drug-induced lung disorder with treatment needs;

• Cardiac insufficiency;

• Abnormal and clinically significant QTc on ECG or need of concomitant use of any drug known to prolong QT interval and cause torsades de pointes;

• Uncontrolled hypertension after drug treatment;

• Uncontrolled hyperglycaemia, acute attack of cholelithiasis, and susceptibility to acute pancreatitis;

• Severe or uncontrolled systemic diseases causing expected intolerance to the investigational drug as judged by the investigator;

• Toxic reactions associated with prior surgery and prior antineoplastic therapies that have not recovered and may affect the subject safety as assessed by the investigator.

• Clinically significant active bacterial, fungal or viral infections, including a positive result for hepatitis B surface antigen and HBV DNA = ULN, one or more positive results for hepatitis C antibody or HIV antibody, or the presence of any uncontrolled infection.

• Use of strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with a narrow therapeutic window within two weeks prior to the first dose of the investigational drug;

• Pregnant and breastfeeding female;

• Women of childbearing age who are unwilling or unable to use acceptable methods for contraception during the entire treatment period in the trial and within 6 months after the last dose of the investigational drug (women of childbearing age include: any one with menarche, and those who have not received successful artificial sterilization [hysterectomy, bilateral fallopian tube ligation, or bilateral oophorectomy] or premenopausal women); a fertile male patient who is unwilling or unable to take effective contraceptive measures, and whose partner is a woman of childbearing age;

• Being involved in other clinical studies (except for the non-interventional phase of interventional clinical study, such as survival follow-up period); less than 4 weeks from the end of the dose of other investigational drug to the first dose of the investigational drug or 5 half-lives of the previous drug, whichever is shorter;

• Any mental or cognitive disorders which may limit subjects' understanding and implementation of the informed consent form;

• Other situations, such as poor compliance, which are considered by the investigator to be not suitable for participation in the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• TGRX-326
Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
• Crizotinib
Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Shenzhen TargetRx, Inc.	Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Plasma Cmax	To measure plasma TGRX-326 concentration	Day 1 of Cycle 2, 3 and 5 (each cycle is 28 days)
Primary	Progression Free Survival (PFS) by independent review committee (IRC)	PFS defined by the time from randomization to progressive disease or death of any cause; PFS as evaluated by independent review committee (IRC).	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Progression Free Survival (PFS) by investigator	PFS defined by the time from randomization to progressive disease or death of any cause; PFS as evaluated by investigator.	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	One-year Progression Free Survival (PFS)	One-year PFS defined by the time from randomization to progressive disease or death of any cause, with data collection up to 1 year from randomization; one-year PFS as evaluated by investigator or IRC.	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Objective Response Rate (ORR)	ORR defined by the ratio of patients who reached the treatment response; ORR as evaluated by independent review committee (IRC) and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Duration of Response (DOR)	DOR defined as the duration from first occurence of treatment response to progressive disease/relapse; DOR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Disease Control Rate (DCR)	DCR defined by the ratio of patients who reached the treatment response or maintained as stable disease; DCR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Time to Response (TTR)	TTR defined by the time from the start of treatment to the first ORR; TTR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Intracranial Objective Response Rate (IC-ORR)	IC-ORR defined by the ratio of patients who reached the intracranial treatment response; ORR as evaluated by IRC and investigator.	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Intracranial Disease Control Rate (IC-DCR)	IC-DCR defined by the ratio of patients who reached the treatment response intracranially or maintained as stable disease; IC-DCR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Intracranial Duration of Response (IC-DOR)	IC-DOR defined as the duration from first occurrence of Intracranial treatment response to progressive disease/relapse; DOR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Intracranial Time to Response (IC-TTR)	IC-TTR defined by the time from the start of treatment to the first IC-ORR; TTR as evaluated by IRC and investigator	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Intracranial Progression Free Survival (IC-PFS)	IC-PFS defined by the time from randomization to progressive disease or death of any cause in patients with intracranial lesions; PFS as evaluated by IRC and investigator.	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Overall Survival (OS)	OS defined by the time from randomization to death of any cause	Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Secondary	Adverse Events (AEs)	To record and analyze subjects with adverse events (AEs)	At Screening; Day 1 of every Cycle (each cycle is 28 days) until end of study
Secondary	Serious Adverse Events (SAEs)	To record and analyze subjects with serious adverse events (SAEs)	At Screening; Day 1 of every Cycle (each cycle is 28 days) until end of study